文献速递白血病

双突变CCAAT/增强子结合蛋白α(CEBPAdm)急性髓系白血病的预后因素

The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm).
PubMed 文献 · Br J Haematol · 2022-03-10

这项回顾性研究纳入171例连续新诊断的CEBPAdm急性髓系白血病患者,采用Cox比例风险回归模型分析预后因素。单因素分析显示CSF3R和WT1突变与较差的无复发生存期(RFS)相关,含高三尖杉酯碱或中剂量阿糖胞苷的诱导方案与较好的RFS和总生存期(OS)相关。含高三尖杉酯碱和中剂量阿糖胞苷的诱导方案较传统柔红霉素加阿糖胞苷方案RFS和OS最优。多因素分析显示含中剂量阿糖胞苷的诱导方案和CSF3R突变是RFS的独立预后因素。

要点

  • CSF3R和WT1突变与CEBPAdm急性髓系白血病较差的无复发生存期相关
  • 含高三尖杉酯碱或中剂量阿糖胞苷的诱导方案与较好的RFS和OS相关
  • 多因素分析显示含中剂量阿糖胞苷的诱导方案和CSF3R突变是RFS的独立预后因素

核心结论

  • 诱导方案和CSF3R突变是CEBPAdm急性髓系白血病的独立预后因素。

研究设计与样本

  • 回顾性研究,纳入171例连续新诊断的CEBPAdm急性髓系白血病患者,采用Cox比例风险回归模型分析。

主要发现

  • 单因素分析显示CSF3R和WT1突变与较差的无复发生存期(RFS)相关。
  • 含高三尖杉酯碱或中剂量阿糖胞苷的诱导方案与较好的RFS和总生存期(OS)相关。
  • 含高三尖杉酯碱和中剂量阿糖胞苷的诱导方案3年RFS为84.7%、3年OS为92.8%,传统柔红霉素加阿糖胞苷方案3年RFS为27.7%(HR 0.126,95%CI 0.051-0.313,Wald P<0.001)、3年OS为56.4%(HR 0.179,95%CI 0.055-0.586,Wald P=0.005)。
  • 多因素分析显示含中剂量阿糖胞苷的诱导方案(HR 0.364,95%CI 0.205-0.646,Wald P<0.001)和CSF3R突变(HR 2.667,95%CI 1.276-5.572,Wald P=0.009)与RFS独立相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prognostic factors to stratify acute myeloid leukaemia (AML) with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm) into different risk groups remains to be determined. In this retrospective study, we evaluated 171 consecutive patients with newly diagnosed AML with CEBPAdm by a Cox proportional hazards regression model. In univariate analyses, colony stimulating factor 3 receptor (CSF3R) and Wilms tumour 1 (WT1) mutations were associated with poor relapse-free survival (RFS). The induction regimens including homoharringtonine (omacetaxine mepesuccinate) or intermediate-dose cytarabine was associated with favourable RFS and overall survival (OS). The induction regimen including both homoharringtonine and intermediate-dose cytarabine was associated with the most favourable RFS (3-year RFS 84.7%) and OS (3-year OS 92.8%) compared to the conventional cytarabine and daunorubicin regimen (3-year RFS 27.7%, hazard ratio [HR] 0.126, 95% confidence interval [CI] 0.051-0.313, Wald p < 0.001; and 3-year OS 56.4%, HR 0.179, 95% CI 0.055-0.586, Wald p = 0.005). In multivariate analyses, the induction regimen including intermediate-dose cytarabine (HR 0.364, 95% CI 0.205-0.646, Wald p < 0.001) and CSF3R mutations (HR 2.667, 95% CI 1.276-5.572, Wald p = 0.009) were independently associated with RFS. Taken together, we found that induction regimen and CSF3R mutations were independent prognostic factors for AML with CEBPAdm.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Wei H, Zhou C, Liu B, et al. The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm). Br J Haematol. 2022. PMID: 35274287. doi:10.1111/bjh.18113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。